- FDA approves Roche’s Vabysmo prefilled syringe (PFS) for three leading causes of vision loss
- [Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell lung cancer
- Roche’s Vabysmo gets CHMP recommendation for third indication retinal vein occlusion (RVO)
- CHMP recommends EU approval of Roche’s PiaSky for people with PNH, a rare, life-threatening blood condition
- Roche expands access to cervical cancer screening tools with two new WHO prequalification designations, including HPV self-collection
- Roche’s OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis
- Roche launches new analytical units for cobas® pro integrated solutions delivering greater efficiency and capacity to laboratories
- Roche launches new highly-sensitive test to more easily diagnose patients who may have B-cell lymphoma
- Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
- Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization
More ▼
Key statistics
On Friday, Roche Holding AG (RO:SWX) closed at 269.60, -9.77% below its 52-week high of 298.80, set on Jul 24, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 268.60 |
---|---|
High | 271.80 |
Low | 268.00 |
Bid | 260.00 |
Offer | 260.00 |
Previous close | 268.00 |
Average volume | 29.22k |
---|---|
Shares outstanding | 809.25m |
Free float | 731.55m |
P/E (TTM) | 17.01 |
Market cap | 199.70bn CHF |
EPS (TTM) | 14.30 CHF |
Annual div (ADY) | 9.60 CHF |
---|---|
Annual div yield (ADY) | 3.56% |
Div ex-date | Mar 14 2024 |
Div pay-date | Mar 18 2024 |
Data delayed at least 15 minutes, as of Jul 05 2024 16:32 BST.
More ▼